Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine

Headache

Volumn 38, Issue 10, 1998, Pages 748-755

  Tfelt Hansen, Peer ^a   Teall, Judith ^b   Rodriguez, Francisco ^c   Giacovazzo, Mario ^d   Paz, Jose ^e   Malbecq, William ^f   Block, Gilbert A ^b   Reines, Scott A ^b   Visser, W Hester ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Fund Inst Neurologico de Columbia   (Colombia)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Sharp and Dohme Inc ^*

^f Merck Sharp and Dohme   (Belgium)

Author keywords

Migraine; Rizatriptan; Sumatriptan

Indexed keywords

PLACEBO; RIZATRIPTAN; SUMATRIPTAN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; VERTIGO; VOMITING;

EID: 0032407703     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3810748.x     Document Type: Article

References (16)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1998;8(suppl 7):1-96.
2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991;44:1147-1157.
3. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333-339.
4. Göbel H, Petersen-Braun M, Heinze A. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. New York: Lippincott-Raven; 1997:6:93-97.
5. Beer M, Middlemiss D, Stanton J, et al. An in-vitro pharmacological profile of rizatriptan. Cephalalgia. 1997;17:390. Abstract.
6. Longmore J, Razzaque Z, Hargreaves RJ, et al. Rizatriptan selectively contracts human middle meningeal over coronary artery: comparison with sumatriptan. Cephalalgia. 1997;17:388-389. Abstract.
7. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997;328:61-64.
8. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40.
9. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan versus sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol. 1996;53:1132-1137.
10. 1D agonist. Br J Clin Pharmacol. 1997;43:49-54.
11. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmaco-kinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
12. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
13. Moteller F, Gilbert JP, McPeek BM. Assessing time-to-an-event as an endpoint: reporting survival analysis. In: Lang ThA, ed. How to Report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers. Philadelphia: American College of Physicians; 1997:137-154.
14. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer. Biometrics. 1978;34:57-67.
15. Whitehead J. The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med. 1989;8:1439-1454.
16. Hochberg Y. A sharp Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.